Selective FXR Agonists for Dyslipidemia Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for dyslipidemia and related cardiovascular diseases, such as atherosclerosis, lack effective compounds that can selectively modulate the farnesoid X receptor (FXR) to improve lipid profiles, including raising HDL levels and lowering LDL and triglycerides.
Innovation Solution
Development of novel, selective, and potent FXR agonists represented by specific compounds that modulate FXR activity to beneficially regulate lipid profiles, including raising HDL levels, lowering LDL and VLDL cholesterol, and reducing triglycerides.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional treatments are used for dyslipidemia, then general lipid management is achieved, but selective modulation of FXR receptor to improve specific lipid profiles (HDL, LDL, triglycerides) is insufficient
Solution Approach 1:
The patent applies parameter changes by developing compounds with specific molecular structures (formula I) that have optimized chemical parameters to selectively bind and modulate the FXR receptor. The compounds feature specific substituent groups (R1-R12, Ar1) with defined chemical properties that enhance receptor selectivity and modulatory efficacy, transforming general lipid management into targeted FXR-mediated lipid profile improvement
Solution Approach 2:
The invention employs composite material principles by creating complex molecular structures that combine multiple functional groups and substituents in a single compound framework. These composite molecular structures (with isoxazole or thiophene cores, various aromatic groups, and substituted alkyl chains) work synergistically to achieve selective FXR receptor binding and potent lipid-modulating effects that conventional single-function compounds cannot accomplish
2Reliability
If novel FXR agonists are developed to selectively modulate FXR receptor, then lipid profile improvement is achieved, but compound complexity increases
Solution Approach 1:
The patent applies segmentation by dividing the complex molecular structure into distinct functional segments: a core heterocyclic unit (isoxazole or thiophene), aromatic substituent groups (R1-R7), and alkyl chain portions (R8-R12). This segmented architecture allows each segment to contribute specifically to receptor binding, selectivity, or pharmacokinetic properties, making the overall complex structure more manageable and designable through modular assembly
Solution Approach 2:
The invention implements local quality by assigning specific functional characteristics to different regions of the molecule. For example, certain substituent positions (R1-R7) are designed with electron-withdrawing or electron-donating properties, while specific chain lengths and branching patterns (R8-R12) are optimized for membrane permeability and receptor interaction. This localized functional differentiation enables the complex molecule to achieve high selectivity without requiring uniform complexity throughout the entire structure
Data Source
AI summary
Compounds of formula and their pharmaceutical compositions and methods of use are disclosed as useful for treating dyslipidemia and related diseases.